2044 -- End Price Gouging for Medications Act | Poliscope

End Price Gouging for Medications Act

2044

118th Congress

Health

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

June 20, 2023

Latest Action

June 20, 2023

Primary Sponsor

Jeff MerkleyDemocratic(OR)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

0pct

0d open

vs 5,649 other S bills in the 118th — cohort avg 33d

Summary

No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.

Lobbying filings that explicitly cite this bill (1)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (1)

PUBLIC CITIZEN (1)

PUBLIC CITIZENclient→PUBLIC CITIZEN

2024 · fourth_quarter · Pharmacy

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.